108 / 144
108
PERGUNTAS & RESPOSTAS
EMD
- Edema Macular Diabético
4. Massin P, Erginay A, Tadayoni R, et al. Ef%cacy and safety of sustained-delivery `uoci-
nolone acetonide intravitreal implant in patients with chronic diabetic macular edema
insuf%ciently responsive to available therapies: a real-life study. Clinical Ophthalmolo-
gy. 2016;10:1257-1264.
5. Tang J, Kern TS. In`ammation in diabetic retinopathy. Prog Retin Eye Res. 2011;30:343-
358.
6. Bressler N, Varma R, Suñer IJ, et al. RIDE and RISE Research Groups. Vision-related
function after ranibizumab treatment for diabetic macular edema: results from RIDE and
RISE. Ophthalmology. 2014; 12:2461-2472.
7. Fechter C, Frazier H, Marcus WB, et al. Ranibizumab 0.3 mg for Persistent Diabetic
Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial.
Ophthalmic Surg Lasers Imaging Retina. 2016; 47:1-18.
8. Gillies C, Sutter K, Simpson M, et al. Intravitreal triamcinolone for refractory diabetic
macular edema: two-year results of a double-masked, placebo-controlled, randomized
clinical trial. Ophthalmology. 2006;113:1533-1538.
9. Das A, McGuire G, Rangasamy S. Diabetic macular edema: pathophys¬iology and
novel therapeutic targets. Ophthalmology. 2015;122:1375-1394.
10. Wells JA, Glassman AR, Ayala AR, et al; Diabetic Retinopathy Clinical Research
Network. A`ibercept, bevacizumab, or ranibizumab for diabetic macular edema. N
Engl J Med. 2015;372:1193-1203.
11. Avery L, Gordon M. Systemic safety of prolonged monthly anti-vascular endothelial
growth factor therapy for diabetic macular edema: a systematic review and meta-analy-
sis. JAMA Ophthalmology. 2015:21-29.
12. David S. Boyer, D, Young Y, Three-Year, Randomized, Sham-Controlled Trial of Dexame-
thasone Intravitreal Implant in Patients with Diabetic Macular Edema. Ophthalmology.
2014; 121:1904-1914.
13. Augustin J, Kuppermann D, Lanzetta P, et al. Ozurdex MEAD Study Group: Dexame-
tasone intravitreal implant in previous treated patients with diabetic macular edema:
subgroup analysis of the MEAD study. BMC Ophthalmol. 2015;15:150.
14. Lazic R, Lukic M, Boras I, et al. Treatment of anti-vascular endothelial growth factor-
-resistant diabetic macular edema with dexamethasone intra-vitreal implant. Retina.
2014;34:719-724.
15. Total Y, Guler E, Guragac B. Dexamethasone intravitreal implant for chronic diabe-
tic macular edema resistant to intravitreal bevacizumab treatment. Curr Eye Res.
2015;22:1-7.
16. Dutra M, Pastorino M, Navarro R et al. Dexamethasone intravitreal implant for treatment
of patients with persistent diabetic macular edema. Ophthalmologica. 2014;231:141-
146.
17. Aknin I, Melki L. Longitudinal Study of Sustained-Release Dexamethasone Intravitreal
Implant in Patients with Diabetic Macular Edema. Ophthalmologica. 2016; 235:187-8.
18. Campochiaro PA, Brown DM, Pearson A, et al; FAME Study Group. Long-term bene%t of
sustained-delivery `uocinolone acetonide vitreous inserts for diabetic macular edema.
Ophthalmology. 2011;118:626-635.
19. Campochiaro PA, Brown DM, Pearson A, et al; FAME Study Group. Sustained delivery
`uocinolone acetonide vitreous inserts provide bene%t for at least 3 years in patients
with diabetic macular edema. Ophthalmology. 2012;119:2125-2132.
20. Ibraheem G, david s, Maged H, et al. Diabetic macular edema Outcomes in eyes trea-
ted with `uocinolone acetonid intravitreal implant: Real-world UK experience. Eur J